Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Should read Marker Cap not sp doh
When a cpmpany gets to this stage of developement the only criteria for the sp is profit.
The sp will go to 10 times annual peofit. It just takes time.
Yes, My fear too, 'more of the same' in a different format.
one sure way to have improved the SP and confidence, would have been for the board to have bought in before the 'closed period'. Let's hope the PR machine has been busy in the background.
The RedX delisting announcement today is a wake up call. Worth over 100p a few years ago, and sub-20p last Thursday, and 6p today - far below its broker valuation of 130p per share.
Sound familiar? Like RedX, Futura has a current share price around £1 lower than its broker valuation.
Being publicly quoted is not for every company, because valuation may become disconnected from progress on fundamentals. It’s a problem that not all company managements and their advisers are up to resolving.
On 10 April, James Barder will no doubt repeat a long list of (known) operational positives over the past year. But one he won’t voluntarily touch on is the share price, which is half its level of 3 years ago, and more than 20% lower than the last time he formally spoke to investors, last September. Quoted companies live or die by their share price. Investors continue to be ‘Doubting Thomases’ with respect to the overall financial worth of Futura’s list of operational accomplishments. He really needs to sing a different song to us on 10 April. We know he’ll re-hash almost verbatim the trading statement, 58% gross margin, additional country launches, tie up with Haleon, blah, blah, blah. We also know he’ll say more about derivatives of Eroxon - packaging, delivery etc, perhaps even usage for women. Will any of this get the share price up to around £1.30, the broker target? I think more will be needed. Actual launch of Eroxon in the US, news of a solid licensing partner in China, sales triggering additional / improved royalties, and news of near term profitability and start of dividend payments. A dividend payout would provide a concrete way of valuing the company, and signal management’s confidence in the company’s financial future, based on its expectations of sales growth and how this will trigger further / higher royalty payments.
It would be very dispiriting to listen to James bumble along as in the past, providing a heavily scripted, largely already known, set of news. It would mean another 6 months at least of a languishing share price. One way or another, that is not a sustainable situation, either for Futura’s executives, or for the company. The far higher value inherent in the company - implicit for years in the broker valuations north of £1 - must be unlocked. If not by the current team and its advisers, then by others with more focus on delivering better share price performance.
In the end, that’s all we really care about as investors.
Comek, I hope you're right, but maybe a nudge might help....
in the past they really haven't given much information away, in fact I've always found the final results pretty poor...but the meetings they after tend to be more informative....but I am not a fan of this board.....but very happy to be proven wrong....
They may include the points you raise in the results release.
Hopefully the results should be exciting particularly looking forward, no least progress in the US. I think they will.
Cheers Darth and Surfie. I've put those into a draft email. Once I get some more things to put in the email I will send it and let peeps know if I get a response.
They do tend to respond but don't really give much away, but what know unless you try....
I'm hoping that they will drill down what units were sold per country release and what royalties they made from each unit. Put some meat on the bones for the future year.
What other products are the company working on or have they been pit on a backburner? If not at what stage are they?
The results are due out on the 10th April and we've already been told how much they think they've made, around 3.3m quid. As we know the amount what else do peeps want to hear from FUM bod...
I want good updates on the US and woud like to see a timeline for them getting the product to market. But I think that will be up to Haleon, so that might be wishful thinking.
I'd also like to hear about which countries are now selling Eroxon and if possible an idea of the amoun of monies they've made between Jan - Marh 24 - again I think this will be wishful thinking because they don't have a large workforce.
What else do peeps want to hear from the bod. I was thinking if I get a list of things we'd like to hear I would email the company and see if the respond on the 10th....
Thanks KD.
I take it thats only listing the European Countries. As South Korea and UAE are stocking?
Https://www.eroxon.es/ this is the link to the Spanish site.
company said earlier this year that they wouldn't release an RNS for each country that went live. Just have to wait for the news on the 10th April when they release their annual figures.
https://www.eroxon.co.uk/instructions - if you go to this site and go to the bottom right hand side of the page you'll see the list of countries. All are live links apart from Portugal and Italy.
Did somebody say they were able to buy Erexon off the shelf in Spain.
I might have missed an RNS ref a launch in Spain. If there wasnt one, looks like they are holding back on positive news for whatever reason.
It is difficult to know exactly what is meant by 10 launches,as 'alunch seems to be a slightly fluid concept.we did have the option exercised by N8 for 14 additional south american countries (a not insignificant thing in itself), but i assume none of these were included in the scope of the reference to 10 new, as they were the result of the option exercise. however, i'm personally not too bothered by whether or not anything is announced, as the important news re launches/marketing is principally the US and china. also im not getting too excited by what figures are given in the results as i still think it is very early days. im more inclined to take a slightly longer term view from the perspective of the current and potential totality of the aggregated markets. there is a map on fum's website which give an indication of the reach. mightily impressive imo. i accept that there will be other views of course.
I was wrong thinking the 10 new countries would be announced this week so guess they will let us know with the results.
Not surprised at no open shorts. Shorts are Usually a bet on a large anticipated drop, possibly after some outcome.
I can not see any significant drop, even if early results are not as expected. Nothing will change. Eroxon will still work, however many new markets will open and demand will pickup. Current market cap only reflects the status quo. There's so much more to come.
From this LSE board:
FUM Short positions.
Open Short Positions in Futura Medical
There are currently no open short positions in Futura Medical.
I dont believe there any significant short positions.
Shorts are closing as the results loom large in the mirro.. They all know it would blow them out.
Bodes well that the 2 countries they have been selling in for 12month, Eroxon has won awards! Don’t see why this won’t continue into all countries! I would also like to see FUM pick back up where they left off with the other potential products or least a timeline to when that will be! What would the SP have been if they’d had the funds & the R&D had continued??? If the company was sold what are these products worth??
We should get a limited indication of potential profitability on April10 regarding the approximate 6 months sales of EROXON.
However all details regarding the U.S. launch will have to come initially from HALEON the appointed distributor
GLA long term FUMSTERS.
ARTURO.
10th April will be the turning point for this Share! With hopefully a clear focus on financials & a detailed plan for the next 12month with profit forecasts, USA timescales to market & ROTW! If not & the BOD give nothing away SP will plummet IMO!
It is beyond my comprehension that punters can’t sit on their hands for a couple of weeks.
I am convinced that the investor presentation will be positive and there will be an upward revision in the share price.
As I have observed several times in the passed most PI’s never make a profit because they never buy or sell at the right time.
For the avoidance of doubt I bought a significant number of share in the placement at 7p. I could have tried to trade but resisted.Not trusting my timing.
I am waiting for the buyout that will surely come.
We are pleased to share that #Eroxon is the winner of the Best Big Budget OTC Marketing Campaign Award at Citeline's OTC Marketing Awards